Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13366189 | 0.87 | FAAH (0.50) | FAAHCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL1168572 | 0.86 | HSD11B1 (0.48) | HSD11B1TYRO3 | |
| SCHEMBL2365642 | 0.86 | FAAH (0.52) | FAAHHSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL2365637 | 0.80 | HSD11B1 (0.43) | HSD11B1TYRO3 | |
| SCHEMBL1168415 | 0.78 | TYRO3 (0.48) | HSD11B1TYRO3 | |
| SCHEMBL3328670 | 0.77 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL13320278 | 0.77 | HSD11B1 (0.46) | HSD11B1TYRO3 | |
| SCHEMBL2365612 | 0.77 | HSD11B1 (0.47) | HSD11B1TYRO3 | |
| SCHEMBL3328689 | 0.76 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL2365689 | 0.75 | MRGPRX4 (0.66) | FAAHCYP2C9CYP3A4CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | claimed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | claimed |
| EP-2362730-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2011-09-07 | — | — | EP | claimed |
| WO-2010059618-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-27 | — | — | WO | claimed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HSD11B1, HSD17B11, HSD3B1 | FAAH 107/4885HSD11B1 1/4885TYRO3 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.